Is BHC or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Nuvalent's return on equity of -40.11% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -11.47% -2,922.77% 5.63% Nuvalent N/A -40.11% -35.43%

Does the media refer more to BHC or NUVL?

In the previous week, Nuvalent had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Nuvalent and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.20 beat Nuvalent's score of 0.16 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to BHC or IBRX?

In the previous week, ImmunityBio had 9 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Bausch Health Cos. ImmunityBio's average media sentiment score of 0.50 beat Bausch Health Cos' score of 0.20 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QGEN or BHC more profitable?

Qiagen has a net margin of 19.16% compared to Bausch Health Cos' net margin of -11.47%. Qiagen's return on equity of 14.40% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Bausch Health Cos -11.47% -2,922.77% 5.63%

Does the media prefer QGEN or BHC?

In the previous week, Qiagen had 12 more articles in the media than Bausch Health Cos. MarketBeat recorded 15 mentions for Qiagen and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.20 beat Qiagen's score of -0.55 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IMVT or BHC?

In the previous week, Immunovant had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Immunovant and 3 mentions for Bausch Health Cos. Immunovant's average media sentiment score of 0.55 beat Bausch Health Cos' score of 0.20 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BHC or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Vaxcyte's return on equity of -32.51% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -11.47% -2,922.77% 5.63% Vaxcyte N/A -32.51% -29.51%

Does the media favor BHC or PCVX?

In the previous week, Vaxcyte had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Bausch Health Cos. Vaxcyte's average media sentiment score of 0.37 beat Bausch Health Cos' score of 0.20 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Bausch Health Cos (BHC) Competitors

$5.32 -0.05 (-0.84%)

Closing price 03:59 PM Eastern

Extended Trading

$5.32 +0.00 (+0.08%)

As of 06:47 PM Eastern

Compare

BHC vs. NUVL, IBRX, QGEN, IMVT, and PCVX

Should you buy Bausch Health Cos stock or one of its competitors? MarketBeat compares Bausch Health Cos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch Health Cos include Nuvalent (NUVL), ImmunityBio (IBRX), Qiagen (QGEN), Immunovant (IMVT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Bausch Health Cos compare to Nuvalent?

Bausch Health Cos (NYSE:BHC) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Nuvalent had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Nuvalent and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.20 beat Nuvalent's score of 0.16 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Bausch Health Cos has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Nuvalent's return on equity of -40.11% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Nuvalent	N/A	-40.11%	-35.43%

Bausch Health Cos currently has a consensus price target of $8.00, suggesting a potential upside of 50.52%. Nuvalent has a consensus price target of $140.29, suggesting a potential upside of 50.84%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Nuvalent beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to ImmunityBio?

Bausch Health Cos (NYSE:BHC) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Bausch Health Cos has a net margin of -11.47% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
ImmunityBio	-606.15%	N/A	-59.53%

Bausch Health Cos has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A
ImmunityBio	$113.29M	66.93	-$351.40M	-$0.85	N/A

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 50.52%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 96.13%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 69.5% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 9 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Bausch Health Cos. ImmunityBio's average media sentiment score of 0.50 beat Bausch Health Cos' score of 0.20 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImmunityBio beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Qiagen?

Qiagen (NYSE:QGEN) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Qiagen has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.57	$424.88M	$1.91	18.93
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

In the previous week, Qiagen had 12 more articles in the media than Bausch Health Cos. MarketBeat recorded 15 mentions for Qiagen and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.20 beat Qiagen's score of -0.55 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a net margin of 19.16% compared to Bausch Health Cos' net margin of -11.47%. Qiagen's return on equity of 14.40% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Qiagen currently has a consensus target price of $44.98, suggesting a potential upside of 24.40%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 50.52%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Qiagen beats Bausch Health Cos on 12 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Immunovant has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Immunovant's return on equity of -65.66% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

47.1% of Immunovant shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bausch Health Cos has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

In the previous week, Immunovant had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Immunovant and 3 mentions for Bausch Health Cos. Immunovant's average media sentiment score of 0.55 beat Bausch Health Cos' score of 0.20 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant presently has a consensus target price of $37.33, suggesting a potential upside of 13.61%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 50.52%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Immunovant beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to Vaxcyte?

Bausch Health Cos (NYSE:BHC) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Bausch Health Cos currently has a consensus price target of $8.00, suggesting a potential upside of 50.52%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 75.83%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Vaxcyte had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Bausch Health Cos. Vaxcyte's average media sentiment score of 0.37 beat Bausch Health Cos' score of 0.20 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bausch Health Cos has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Vaxcyte's return on equity of -32.51% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Vaxcyte	N/A	-32.51%	-29.51%

Bausch Health Cos has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Vaxcyte beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.99B	$5.88B	$6.31B	$23.24B
Dividend Yield	N/A	0.68%	2.68%	4.09%
P/E Ratio	-1.64	8.56	21.13	30.90
Price / Sales	0.19	22.35	546.66	24.20
Price / Cash	0.74	8.53	27.44	19.43
Price / Book	5.21	4.16	9.95	4.72
Net Income	$157M	$102.24M	$3.56B	$1.07B
7 Day Performance	-2.74%	1.86%	2.12%	1.37%
1 Month Performance	N/A	N/A	N/A	0.45%
1 Year Performance	17.33%	132.29%	36.32%	27.94%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.996 of 5 stars	$5.32 -0.8%	$8.00 +50.5%	+18.4%	$1.99B	$10.27B	N/A	20,300
NUVL Nuvalent	3.4502 of 5 stars	$102.12 flat	$140.29 +37.4%	+49.9%	$8.07B	N/A	N/A	40	News Coverage Insider Trade
IBRX ImmunityBio	2.8818 of 5 stars	$7.22 flat	$14.20 +96.7%	+181.6%	$7.56B	$113.29M	N/A	590
QGEN Qiagen	4.2098 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-22.9%	$7.25B	$2.09B	18.40	5,654	Analyst Downgrade
IMVT Immunovant	2.022 of 5 stars	$34.15 flat	$35.33 +3.5%	+123.9%	$7.01B	N/A	N/A	120	Negative News Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. NUVL, IBRX, QGEN, IMVT, and PCVX

How does Bausch Health Cos compare to Nuvalent?

Summary

How does Bausch Health Cos compare to ImmunityBio?

Summary

How does Bausch Health Cos compare to Qiagen?

Summary

How does Bausch Health Cos compare to Immunovant?

Summary

How does Bausch Health Cos compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. NUVL, IBRX, QGEN, IMVT, and PCVX

How does Bausch Health Cos compare to Nuvalent?

Does the media refer more to BHC or NUVL?

Which has more volatility and risk, BHC or NUVL?

Which has stronger valuation and earnings, BHC or NUVL?

Is BHC or NUVL more profitable?

Do analysts prefer BHC or NUVL?

Do insiders and institutionals believe in BHC or NUVL?

Summary

How does Bausch Health Cos compare to ImmunityBio?

Is BHC or IBRX more profitable?

Which has more volatility & risk, BHC or IBRX?

Which has higher earnings and valuation, BHC or IBRX?

Do analysts rate BHC or IBRX?

Do institutionals and insiders have more ownership in BHC or IBRX?

Does the media refer more to BHC or IBRX?

Summary

How does Bausch Health Cos compare to Qiagen?

Which has stronger earnings and valuation, QGEN or BHC?

Does the media prefer QGEN or BHC?

Is QGEN or BHC more profitable?

Do institutionals & insiders believe in QGEN or BHC?

Do analysts rate QGEN or BHC?

Which has more volatility and risk, QGEN or BHC?

Summary

How does Bausch Health Cos compare to Immunovant?

Is IMVT or BHC more profitable?

Do institutionals and insiders hold more shares of IMVT or BHC?

Which has higher earnings & valuation, IMVT or BHC?

Which has more volatility and risk, IMVT or BHC?

Does the media favor IMVT or BHC?

Do analysts recommend IMVT or BHC?

Summary

How does Bausch Health Cos compare to Vaxcyte?

Do analysts prefer BHC or PCVX?

Does the media favor BHC or PCVX?

Do institutionals & insiders hold more shares of BHC or PCVX?

Which has more risk & volatility, BHC or PCVX?

Is BHC or PCVX more profitable?

Which has preferable valuation & earnings, BHC or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools